185 related articles for article (PubMed ID: 25664933)
1. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
2. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
4. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
5. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
6. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Abdel-Rahman O; Elhalawani H
Future Oncol; 2015; 11(7):1109-22. PubMed ID: 25804125
[TBL] [Abstract][Full Text] [Related]
7. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Shi L; Tang J; Tong L; Liu Z
Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
[TBL] [Abstract][Full Text] [Related]
8. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Abdel-Rahman O; ElHalawani H; Essam-Eldin S
Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
[TBL] [Abstract][Full Text] [Related]
9. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
10. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Curr Med Res Opin; 2012 Apr; 28(4):643-50. PubMed ID: 22414178
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K
Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800
[TBL] [Abstract][Full Text] [Related]
15. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
17. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
18. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
Choi HD; Chang MJ
PLoS One; 2020; 15(7):e0234818. PubMed ID: 32663210
[TBL] [Abstract][Full Text] [Related]
19. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
[TBL] [Abstract][Full Text] [Related]
20. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
